Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron Janowsky

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
ACS Pharmacology & Translational Science|January 15, 2026
Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved DrugsRebecca Racz, Laura B Kozell, Amy J Eshleman, et al.
Journal of Medicinal Chemistry|April 2, 2016
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist SelectivityMu-Fa Zou, Thomas M Keck, Vivek Kumar, et al.
Clinical Pharmacology and Therapeutics|June 29, 2022
Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac ArrestJohn Mann, Mohammadreza Samieegohar, Anik Chaturbedi, et al.
Biorxiv : the Preprint Server for Biology|March 26, 2024
Development of novel tools for dissection of central versus peripheral dopamine D<sub>2</sub>-like receptor signaling in dysglycemiaAlessandro Bonifazi, Michael Ellenberger, Zachary J Farino, et al.
Diabetes|June 13, 2024
Development of Novel Tools for Dissection of Central Versus Peripheral Dopamine D2-Like Receptor Signaling in DysglycemiaAlessandro Bonifazi, Michael Ellenberger, Zachary J Farino, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 25, 2022
A highly D<sub>3</sub>R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D<sub>3</sub>R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorderEwa Galaj, Guo-Hua Bi, Benjamin Klein, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
ACS Pharmacology & Translational Science|January 15, 2026
Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved DrugsRebecca Racz, Laura B Kozell, Amy J Eshleman, et al.
Journal of Medicinal Chemistry|April 2, 2016
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist SelectivityMu-Fa Zou, Thomas M Keck, Vivek Kumar, et al.
Clinical Pharmacology and Therapeutics|June 29, 2022
Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac ArrestJohn Mann, Mohammadreza Samieegohar, Anik Chaturbedi, et al.
Biorxiv : the Preprint Server for Biology|March 26, 2024
Development of novel tools for dissection of central versus peripheral dopamine D<sub>2</sub>-like receptor signaling in dysglycemiaAlessandro Bonifazi, Michael Ellenberger, Zachary J Farino, et al.
Diabetes|June 13, 2024
Development of Novel Tools for Dissection of Central Versus Peripheral Dopamine D2-Like Receptor Signaling in DysglycemiaAlessandro Bonifazi, Michael Ellenberger, Zachary J Farino, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 25, 2022
A highly D<sub>3</sub>R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D<sub>3</sub>R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorderEwa Galaj, Guo-Hua Bi, Benjamin Klein, et al.
Pageof 7